4-Isoxazolyl-1,4-Dihydropyridines: A Tale of Two Scaffolds

References

• Silverman RB , Organic Chemistry of Drug Design and Drug Action (Second Edition).Academic Press, NY, USA (2004).
   Google Scholar
• Brown N . Bioisosteres in Medicinal Chemistry, Methods and Principles in Medicinal Chemistry (Volume 54).Wiley-VCH, Weinheim, Germany (2012).
   Google Scholar
• Evans B , RittleK, HirshfieldtJbet al. Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists. J. Med. Chem.31 (12), 2235–2246 (1988).
   PubMed Web of Science ®Google Scholar
• Bemis G , MurckoM. The properties of known drugs. 1. Molecular frameworks. J. Med. Chem.39 (15), 2887–2893 (1996).
   PubMed Web of Science ®Google Scholar
• Bemis G , MurckoM. Properties of known drugs. 2. Side chains. J. Med. Chem.42 (25), 5095–5099 (1999).
   PubMed Web of Science ®Google Scholar
• Kelekota J , RothF. Chemical substructures that enrich for biological activity. Bioinformatics24 (21), 2518–2525 (2008).
   PubMed Web of Science ®Google Scholar
• Hajduk P , BuresM, PraestgaardJ, FesikS. Privileged molecules for protein binding identified from NMR-bases screening. J. Med. Chem.43 (18), 3443–3447 (2000).
   PubMed Web of Science ®Google Scholar
• Klabunde T , HesslerG. Drug design strategies for targeting G-protein-coupled receptors. Chembiochem.3 (10), 928–944 (2002).
   PubMed Web of Science ®Google Scholar
• Matter H , BaringhausKH, NaumannT, KlabundeT, PirardB. Computational approaches towards the rational design of drug-like compound libraries. Comb. Chem. High Throughput Screen.4 (6), 4534–75 (2001).
   Web of Science ®Google Scholar
• Brown N . Scaffold Hopping in Medicinal Chemistry, Methods and Principles in Medicinal Chemistry (Volume 58).Wiley-VCH, Weinheim, Germany (2013).
   Google Scholar
• Boehm H-J . Scaffold hopping. Drug Discov. Today Technol.1 (3), 2172–24 (2004).
   Google Scholar
• Welsch M , SnyderS, StockwellB. Privileged scaffolds for library design and drug discovery. Curr. Opin. Chem. Biol.14 (3), 347–361 (2010).
   PubMed Web of Science ®Google Scholar
• Triggle J . 1,4-dihydropyridines as calcium channel ligands and privileged structures. Cell Mol. Neurobiol.23 (3), 293–303 (2003).
   PubMed Web of Science ®Google Scholar
• Jacobson K .; KimY, KingF. In search of selective P2 receptor ligands: interaction of dihydropyridine derivatives at recombinant rat P2X2 receptors. J. Auton. Nerv. Syst.81 (3), 152–157 (2000).
   PubMedGoogle Scholar
• Pevarello P , AmiciR, BrascaMG, VillaM, VarasiM. Recent applications of isoxazole ring in medicinal chemistry. Targets Heterocycl. Syst.3, 301 (1999).
   Google Scholar
• Kubinyi H, Muller G . Chemogenomics in Drug Discovery: A Medicinal Chemistry Perspective.Wiley, Weinheim, Germany (2004).
   Google Scholar
• Claisen L , LowmanO. Zur Kenntniss des Benzoylacetones. Chem. Ber.21, 1149 (1888).
   Google Scholar
• Hantsch A , Ueber die Einwirkung des Natriums auf auf Isobuttersaureather. Justus Liebigs Ann. Chem.1, 249 (1888).
   Google Scholar
• Baumann M , BaxendaleIR, LeySV, NikbinN. An overview of the key routes to the best selling 5-membered ring heterocyclic pharmaceuticals. Beilstein J. Org. Chem.7, 442–495 (2011).
   PubMed Web of Science ®Google Scholar
• Kochetkov NK , SokolovSD. Chemistry of heterocyclic compounds: isoxazoles, Part 1. Adv. Het. Chem.49 (2), 365 (1963).
   Google Scholar
• Wakefield BJ , WrightDJ. Adv. Het. Chem.25, 147 (1979).
   Google Scholar
• Lang SA , LinYI. Comprehensive Heterocyclic Chemistry.PottsKT (Ed). Pergamon Press, NY, USA, 6, 1 (1984).
   Google Scholar
• Grunanger P , Vita-FinziP. Isoxazoles.John Wiley and Sons Inc., NY, USA (1990).
   Google Scholar
• Pinho e Melo TMVD . Recent advances on the synthesis and reactivity of isoxazoles. Current Org. Chem.9 (10), 9259–58 (2005).
   Web of Science ®Google Scholar
• Natale NR , MirzaeiYR. The lateral metalation of isoxazoles. A review. Org. Prep. Proced. Int.25 (5), 515–556 (1993).
   Web of Science ®Google Scholar
• Hantzsch A . Justus Liebigs. Ann. Chemie.215, 1–82 (1882).
   Google Scholar
• Eisner U , KuthanJ. Chemistry of dihydropyridines. Chem. Rev.72 (1), 1–42 (1972).
   Web of Science ®Google Scholar
• Stout DM , MeyersAI. Recent advances in the chemistry of dihydropyridines. Chem. Rev.82 (2), 223–243 (1982).
   Web of Science ®Google Scholar
• Triggle DJ . The 1,4-dihydropyridine nucleus: a pharmacophoric template. MiniRev. Med. Chem.3 (3), 166–175 (2003).
   Web of Science ®Google Scholar
• Zamponi G . Voltage-Gated Calcium Channels.Landes Bioscience, NY, USA (2005).
   Google Scholar
• Triggle DJ , LangsDA, Janis, RA. Ca+2 channel ligands: structure-function relationship of the 1,4-dihydropyridines. Med. Res. Rev.9 (2), 123–180 (1989).
   PubMed Web of Science ®Google Scholar
• Natale NR . Learning from the Hantzsch synthesis, Chem. Innov.30 (11), 22–28 (2000).
   Google Scholar
• Nogae I , KohnoK, GottesmanMet al. Analysis of structural features of dihydropyridine analogs needed to reverse multidrug resistance and to inhibit photoaffinity labeling of P-glycoprotein. Biochem. Pharmacol.38 (3), 519–527 (1989).
   PubMed Web of Science ®Google Scholar
• Gottesman M , FojoT, BatesSE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat. Rev. Cancer2 (1), 48–58 (2002).
   PubMed Web of Science ®Google Scholar
• Gillet JP , GottesmanM. Mechanisms of multi-drug resistance in cancer. In: Multi-Drug Resistance in Cancer.ZhouJ (Ed.). Humana Press,, NY, USA, 47–76 (2010).
   Google Scholar
• Natale NR , QuincyDA. Neutral dichromate oxidations. Preparation and utility of isoxazole aldehydes. Synth. Commun.13, 817–822 (1983).
   Web of Science ®Google Scholar
• Shafu B , AminiM, AkbarzadehT, ShafieeA. Synthesis and antitubercular activity of N3, N5-diaryl14--(5-arylisoxazol-3-yl)-1,4-dihydropyridine-3,5-dicarboxamide. J. Sci. I. R. Iran19, 323–328 (2008).
   Google Scholar
• Daryabari N , AkbarzadehT, AminaM, MiriR, MirkhaniH, ShafieeA. Synthesis and calcium channel antagonist activities of new derivatives of dialkyl 1,4-dihydro-2,6-dimethyl-4-(5-phenylisoxazol-3-yl)pyridine-3,5-dicarboxylates. J. Iran Chem. Soc.4 (1), 30–36 (2007).
   Web of Science ®Google Scholar
• Schauer CK , AndersonOP, Quincy, DA, NataleNR. Structure of 3,5-dicarboethoxy-2,6-dimethyl-4-(3’-phenyl-5’methyl-isoxazol-4’-yl)-1,4-dihydropyridine, A calcium antagonist. Acta Crystallogr. Sect. C Cryst. Struct. Commun.C42, 884–886 (1986)
   Google Scholar
• Knerr GD , QuincyDA, McKennaJI, NataleNR. The mass spectral fragmentation of isoxazolyl-dihydropyridines. J. Heterocycl. Chem.24, 1429–1433 (1987).
   Google Scholar
• McKenna JI , SchlicksuppL, NataleNR, MaryanoffBE, FlaimSF, Willett, RD. Cardioactivity and solid state structure of two 4-isoxazolyl-dihydropyridines related to the 4- aryldihydropyridine calcium channel blockers. J. Med. Chem.31 (2), 473–476 (1988).
   PubMedGoogle Scholar
• Kovacic P , EdwardsWD, NataleNR, SridharR, KiserP. Structure calculations on calcium channel drugs: is electron transfer involved mechanistically?Chem. Biol. Interact.75 (1), 61–70 (1990).
   PubMed Web of Science ®Google Scholar
• Natale NR , TriggleDJ, PalmerRB, LeflerBJ, EdwardsWD. 4-Isoxazolyl-dihydropyridines: biological, theoretical and structural studies. J. Med. Chem.33 (8), 22552–259 (1990).
   Web of Science ®Google Scholar
• Mirzaei YR , SimpsonBM, TriggleDJ, NataleNR. Diastereoselectivity in the lateral metalation and electrophilic quenching of isoxazolyl- oxazolines. J. Org. Chem.57, 6271–6279 (1992).
   Web of Science ®Google Scholar
• Balasubramaniam TN , NataleNR, Electrophilic quenching of dianions of 4-[5’-sulfonylmethylIsoxazolyl]-1,4-dihydropyridines. A direct route to functionalized Hantzsch esters. Tetrahedron Lett.34 (7), 1099–1102 (1993).
   Web of Science ®Google Scholar
• Palmer RB , AndroTM, NataleNR, AndersenNH. Conformational preferences and dynamics of 4-isoxazolyl-1,4-dihydropyridine calcium channel antagonists as determined by variable temperature NMR and NOE experiments. Magn. Reson. Chem.34, 495–504 (1996).
   Web of Science ®Google Scholar
• Natale NR , Rogers, ME, StaplesR, TriggleDJ, RutledgeA. Lipophilic 4-isoxazolyl-1,4-dihydropyridines: synthesis and structure activity relationship. J. Med. Chem.42 (16), 3087–3093 (1999).
   PubMed Web of Science ®Google Scholar
• Natale, NR, NiouCS. A facile synthesis of functionally complex isoxazole derivatives. Tetrahedron Lett.3943–3946 (1984)
   Google Scholar
• Natale NR , McKennaJI, NiouCS, BorthM, HopeH. Metalation of isoxazolyloxazolines, a facile route to functionally complex isoxazoles: utility, scope and comparison with dianion methodology. J. Org. Chem.50, 5660–5666 (1985).
   Web of Science ®Google Scholar
• Niou CS , NataleNR. Synthesis, metalation and electrophilic quenching of alkyl-isoxazole-4-tertiary carboxamides. A critical comparison of three isoxazole lateral metalation methods. Heterocycles24, 4011–4012 (1986).
   Web of Science ®Google Scholar
• Schlicksupp L , NataleNR. Regioselectivity in lateral deprotonation of an isoxazole carboxamide of (S)-prolinol. conformational correlation by crystal structure, solid state and solution 13C NMR. J. Heterocycl. Chem.24, 1345–1348 (1987).
   Web of Science ®Google Scholar
• Campana C , MirzaeiJ, KoernerC, GatesC, NataleNR. 3-(1,3-diphenylpropan-2-yl)-4-methyl-6-phenylisoxazolo[3,4-d]pyridazin-7(6H)-one. Acta Cryst.E69, 1680–1681 (2013).
   Google Scholar
• Zamponi G , StotzSC, StaplesRJ, RogersTA, NelsonJK, HulubeiV, BlumenfeldA, NataleNR. Unique structure activity relationship of 4-isoxazolyl-1,4-dihydropyridines. J. Med. Chem.46 (1), 87–96 (2003).
   PubMed Web of Science ®Google Scholar
• Hulubei V , SteigerSA, NataleNRet al. 4-Isoxazolyl-1,4-dihydropyridines exhibit binding at the multidrug resistance transporter. Bioorg. Med. Chem.20 (22), 6613–6620 (2012).
   PubMed Web of Science ®Google Scholar
• Szabon-Watola MI , UlatowkiSV, GeorgeKM, Hayes, CD, SteigerSA, NataleNR. Fluorescent probes of the isoxazole-dihydropyridine scaffold: MDR-1 binding and homology model. Bioorg. Med. Chem. Lett.24, 117–121 (2014).
   PubMed Web of Science ®Google Scholar
• Mirzaei Y.R ., SamedT, MajidG, HasanN, LadenE. Facile synthesis of isoxazole-4 and 5-carbaldehydes and their conversion to isoxazolyl-1, 4-dihyropyridines. Org. Prep. Proced. Int.35, 207–214 (2003).
   Web of Science ®Google Scholar
• Philips B , HartmanG. Preparation and reaction of isomeric formyl-2,1-benzisoxazoles. J. Het. Chem.23 (3), 897–899 (1986).
   Web of Science ®Google Scholar
• Baldwin J , HalczenkoW, HartmanG, PhilipsB. US4735956A (1988).
   Google Scholar
• Hamama WS , IbrahimME, HanafiH. Zoorob efficient regioselective synthesis and potential antitumor evaluation of isoxazolo[5,4-b]pyridines and related annulated compounds. Arch. Pharm. Chem. Life Sci.345, 468–475 (2012).
   PubMed Web of Science ®Google Scholar
• Laurent S , KimD, SmithTW, MarshJD. Inotropic effect, binding properties, and calcium flux effects of the calcium channels agonist CGP 28392 in intact cultured embryonic chick ventricular cells. Circ. Res.56 (5), 676–682 (1985).
   PubMed Web of Science ®Google Scholar
• Taylor M , HimmelsbachR, KornbergB, QuinJ, LunneyE, MichelA. 1,3-dipolar cycloaddition of nitrile oxides with 1,4-dihydropyridines and conformational analysis of isoxazolo[5,4-b]pyridines. J. Org. Chem.54, 5585–5590 (1989).
   Web of Science ®Google Scholar
• Heaney F . Nitrile oxide/alkyne cycloadditions – a credible platform for synthesis of bioinspired molecules by metal-free molecular clicking. Eur. J. Org. Chem.3043–3058 (2012).
   Web of Science ®Google Scholar
• Hansen TV , WuP, FolkinVV. One pot copper(I)-catalyzed synthesis of 3,5-disubstituted isoxazoles. J. Org. Chem.70, 7761–7764 (2005).
   PubMed Web of Science ®Google Scholar
• Himo F , SharplessKB, FolkinVVet al. Copper(I) -catalyzed synthesis of azoles. DFT study predicts unprecedented reactivity and intermediates. J. Am. Chem. Soc.127, 210–216 (2005).
   PubMed Web of Science ®Google Scholar
• Maass P , Schulz-GaschT, StahlM, RareyM. Recore: a fast and versatile method for scaffold hopping based on small molecule crystal structure conformations. J. Chem. Inf. Model.47, 390–399 (2007).
   PubMed Web of Science ®Google Scholar
• Furuta T , ShibataS, KadamaI, YamadaK. Cardiovascular effects on FR34235, a new dihydropyridine slow channel blocker, in isolated rabbit myocardium and aorta. J. Cardiovasc. Pharmacol.5 (5), 836–841 (1983).
   PubMed Web of Science ®Google Scholar
• Coburn R , WierzbaM, SutoM, SoloA, TriggleA, TriggleD. 1,4-dihydropyridine antagonist activities at the calcium channel: a quantitative structure-activity relationship approach. J. Med. Chem.31, 2103–2107 (1988).
   PubMed Web of Science ®Google Scholar
• Triggle D . 1,4-dihydropyridine calcium channel ligands: selectivity of action. The role of pharmacokinetics, state-dependent interactions, channel isoforms, and other factors. Drug Devel. Res.58, 5–17 (2003).
   Web of Science ®Google Scholar
• Triggle D . Calcium channel ligands. Ann. Rev. Pharmacol. Toxicol.27, 347–369 (1987).
   PubMed Web of Science ®Google Scholar
• Mohajeri A , HemmateenejadB, MehdipourA, MiriR. Modeling calcium channel antagonistic activity of dihydropyridine derivatives using ATMS indices analyzed by GA-PLS and PC-GA-PLS. J. Mol. Graph Model.26 (7), 1057–1065 (2008).
   PubMed Web of Science ®Google Scholar
• Mahmoudian M , RichardsW. A conformational distinction between dihydropyridine calcium agonists and antagonists. Chem. Commun.10, 739–741 (1986).
   Google Scholar
• Mojarrad J , MiriR, KnausE. Design and synthesis of methyl 27-,7-dihalo-5-phenyl-2-azabicyclo[4.1.0]hepta3-ene-4-carboxylates with calcium channel antagonist activity. Bioorg. Med. Chem.12, 3215–3220 (2004).
   PubMedGoogle Scholar
• Bechem M , GoldmannS, GrossRet al. A new type of Ca-channel modulation by a novel class of 1,4 dihydropyridines. Life Sci.60 (2), 1071–1078 (1997).
   Web of Science ®Google Scholar
• Zheng W , StoltefussJ, GoldmannS, TriggleJ. Pharmacologic and radioligand binding studies of 1,4-dihydropyridines in rat cardiac and vascular preparations: stereoselectivity and voltage dependence of antagonist and activator interactions. Mol. Pharmacol.41 (3), 535–541 (1992).
   PubMed Web of Science ®Google Scholar
• Handrock R , HerzigS. Stereoselectivity of Ca+2 channel block by dihydropyridines: no modulation by the voltage protocol. Eur. J. Pharmacol.309 (3), 317–321 (1996).
   PubMed Web of Science ®Google Scholar
• Mahmoudian M , RichardsW. QSAR of binding of dihydropyridine-type calcium antagonists to their receptor on ileal smooth muscle preparations. J. Pharm. Pharmacol.38 (4), 272–276 (1986).
   PubMed Web of Science ®Google Scholar
• Goldmann S , StoltefussJ, BornL. Determination of the absolute configuration of the active amlodipine enantiomer as (-)-S: a correction. J. Med. Chem.35 (18), 3341–3344 (1995).
   Google Scholar
• Goldmann S , StoltefussJ. 1,4-Dihydropyridines: effects of chirality and conformation on the calcium antagonist and agonist activities. Angew. Chem. Int. Ed.30 (12), 1559–1578 (1991).
   Web of Science ®Google Scholar
• Janis RA , SilverPJ, TriggleDJ. Drug action and cellular calcium regulation. Adv. Drug Res.16, 3095–3091 (1987).
   Google Scholar
• Janis RA , TriggleDJ. New developments in calcium ion channel antagonists. J. Med. Chem.26 (6), 775–785 (1983).
   PubMed Web of Science ®Google Scholar
• Rovnyak G , AndersenN, GougoutasJet al. Studies directed towards ascertaining the active conformation of 1,4-dihydropyridine calcium entry blockers. J. Med. Chem.31 (5), 936–944 (1988).
   PubMed Web of Science ®Google Scholar
• Goldman S , GeigerW. Rotational barriers of 4-aryl-1,4-dihydropyridines (Ca antagonists)Angew. Chem. Int. Ed. Engl.23, 301–302 (1984).
   Web of Science ®Google Scholar
• Berntsson P , CarterR.E. Determination of the conformation of felodipine by 1H NMR spin lattice relaxation time measurements. Acta Pharmaceutica Suec.18, 221–226 (1981).
   Google Scholar
• Baldwin JJ , ClaremonDA, LummaPKet al. Diethyl 3, 6-dihydro-2, 4-dimethyl-2, 6-methano-1, 3-benzothiazocine-5, 11-dicarboxylates as calcium entry antagonists: new conformationally restrained analogs of Hantzsch 1, 4-dihydropyridines related to nitrendipine as probes for receptor-site conformation. J. Med. Chem.30 (4), 690–695 (1987).
   PubMed Web of Science ®Google Scholar
• Cosconati S , MarinelliL, LavecchiaA, NovellinoE. Characterizing the 1,4-dihydropyridines binding interactions in the L-type Ca2+ channel: model construction and docking calculations. J. Med. Chem.50 (7), 1504–1513 (2007).
   PubMed Web of Science ®Google Scholar
• Tsuruo T , LidaH, YamashiroM, TsukagoshiS, SakuraiY. Enhancement of vincristine- and adriamycin-induced cytotoxicity by verapamil in P388 leukemia and its sublines resistant to vincristine and adriamycin. Cancer Res.31 (19), 2905–2910 (1983).
   Google Scholar
• Miller T , GorganT, DaltonW. P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil. J. Clin. Oncol.9 (1), 17–24 (1991).
   PubMed Web of Science ®Google Scholar
• Hollt V , KoubaM, DietelM, VogtG. Steroisomers of calcium antagonists which differ markedly in their potencies as calcium blockers are equally effective in modulating drug transport by P-glycoprotein. Biochem. Pharmacol.43 (12), 2601–2608 (1992).
   PubMed Web of Science ®Google Scholar
• Teodori E , DeiS, ScapecchiS, GualtieriF. The medicinal chemistry of multidrug resistance (MDR) reversing drugs. II Farmaco.57 (2), 385–415 (2002).
   PubMedGoogle Scholar
• Tolomeo M , GancitanoR, MussoMet al. Effects of R-enantiomer(GR66234A) and L-enantiomer (GR66235A) of telupidine, a newer dihydropyridine derivative, on cell line displaying the multidrug resistant phenotype. Haematologica79 (4), 328–333 (1994).
   PubMed Web of Science ®Google Scholar
• Tasaka S , OhmoriH, GomiNet al. Synthesis and structure-activity analysis of novel dihydropyridine derivatives to overcome multidrug resistance. Bioorg. Med. Chem. Lett.11 (2), 275–277 (2001).
   PubMed Web of Science ®Google Scholar
• Bazargan L , FouladdelS, ShafieeA, AminiM, GhaffariS, AziziE. Evaluation of anticancer effects of newly synthesized dihydropyridine derivatives in comparison to verapamil and doxorubicin on T47D parental and resistant cell lines in vitro. Cell Biol. Toxicol.24 (2), 165–174 (2008).
   PubMed Web of Science ®Google Scholar
• Saponara S , FerraraA, GorelliBet al. 3,5-dibenzoyl-4-(3-phenoxyphenyl)-1,4-dihydro-2,6-dimethylpyridine (DP7): a new multidrug resistance inhibitor devoid of effects on Langendorff-perfused rat heart. Eur. J. Pharmacol.563 (1), 160–163 (2007).
   PubMed Web of Science ®Google Scholar
• Mehdipour A , JavidniaK, HemmateenejadB, AmirghofranZ, MiriR. Dihydropyridine derivatives to overcome atypical multidrug resistance: design, synthesis, QSAR studies, and evaluation of their cytotoxic and pharmacological activities. Chem. Biol. Drug. Des.70 (4), 337–346 (2007).
   PubMed Web of Science ®Google Scholar
• Mohajeri A , HemmateenejadB, MehdipourA, MiriR. Modeling calcium channel antagonistic activity of dihydropyridine derivatives using QTMS indices analyzed by GA-PLS and PC-GA-PLS. J. Mol. Graph Model.26 (7), 1057–1065 (2008)
   PubMed Web of Science ®Google Scholar
• Zhou X , CoburnR, MorrisM. Effects of new 4-aryl-1,4-dihydropyridines and 4-arylpyridines on drug efflux mediated by multidrug resistance-associated protein 1. J. Pharm. Sci.94 (10), 2256–2265 (2005).
   PubMed Web of Science ®Google Scholar
• Zhou X , YangX, WangQ, CoburnR, MorrisM. Effects of dihydropyridines and pyridines on multidrug resistance mediated by breast cancer resistance protein: in vitro and in vivo studies. Drug Metab. Dispos.33 (8), 1220–1228 (2005).
   PubMed Web of Science ®Google Scholar
• Zhou X , CoburnR, MorrisMet al. New 4-aryl-1,4-dihydropyridines and 4-arylpyridines as P-glycoprotein inhibitors. Drug. Metab Dispos.33 (3), 321–328 (2005).
   PubMed Web of Science ®Google Scholar
• Mary A , ZamponiG. Voltage-dependent inactivation of voltage gated calcium channels. Landes Biosci.90 (1), 484–486 (2005).
   Google Scholar
• Miri R , MehdipourA. Dihydropyridines and atypical MDR: a novel perspective of designing general reversal agents for both typical and atypical MDR. Bioorg. Med. Chem.16 (18), 8329–8334 (2008).
   PubMed Web of Science ®Google Scholar
• Shah A , BariwalJ, MolnárJ, KawaseM, MotohashiN. Advanced dihydropyridines as novel multidrug resistance Modifiers and reversing agents. Top. Heterocycl. Chem.15, 201–252 (2008).
   Google Scholar
• Zhou F , ShaoO, CoburnA, MorrisE. Quantitative structure-activity and quantitative structure-pharmacokinetics relationship of 1,4-dihydropyridines and pyridines as multidrug resistance modulators. Pharm. Res.22 (12), 1989–1996 (2005).
   PubMed Web of Science ®Google Scholar
• Nobili S , LandiniI, GiglioniB, MiniE. Pharmacological strategies for overcoming multidrug resistance. Curr. Drug Targets7 (7), 861–879 (2006).
   PubMed Web of Science ®Google Scholar
• Safa A . Photoaffinity labels for characterizing drug interaction sites of P-glycoprotein. Methods Enzymol.292, 289–307 (1998).
   PubMed Web of Science ®Google Scholar
• Borchers C , BoerR, KlemmKet al. Characterization of the dexniguldipine binding site in the multidrug resistance-related transport protein P-glycoprotein by photoaffinity labeling and mass spectrometry. Mol. Pharm.61 (6), 1366–1376 (2002).
   Web of Science ®Google Scholar
• Greenberg M . Identification of drug interaction sites in P-glycoprotein. Methods Enzymol.263, 307–317 (1998).
   Google Scholar
• Boer R , UlrichW, HaasSet al. Interaction of cytostatics and chemosensitizers with the dexniguldipine binding site on P-glycoprotein. Euro. J. Pharmacology295 (2), 253–260 (1996).
   PubMed Web of Science ®Google Scholar
• Bruggemann P , GermanA, GottesmanM, PastanI. Two different regions of P-glycoprotein are photoafffinty-labeled by azidopine. J. Biol. Chem.264 (26), 15483–15488 (1989).
   PubMed Web of Science ®Google Scholar
• Ferry R , RusselA, CullenH. P-glycoprotein possesses a 1,4-dihydropyridine-selective drug acceptor site which is allosterically coupled to a Vinca alkaloid-selective binding site. Biophys. Res. Commun.188 (1), 440–445 (1992).
   PubMed Web of Science ®Google Scholar
• Ramachandra M , AmbudkarV, ChenDet al. Human P-glycoprotein exhibits reduced affinity for substrates during a catalytic transition state. Biochemistry37 (14), 5010–5019 (1998).
   PubMed Web of Science ®Google Scholar
• Ayesh S , ShaoM, SteinD. Co-operative, competitive and non-competitive interactions between modulators of P-glycoprotein. Biochim. Biophys. Acta1316 (1), 8–18 (1996).
   PubMed Web of Science ®Google Scholar
• Shapiro A , LingV. Positively cooperative sites for drug transport by P-glycoprotein with distinct drug specificities. Eur. J. Biochem.250 (1), 130–137 (1997).
   PubMedGoogle Scholar
• Shapiro A , FoxK, LamP, LingV. Stimulation of P-glycoprotein-mediated drug transport by prazosin and progesterone. Evidence for a third drug-binding site. Eur. J. Biochem.259 (3), 841–850 (1999).
   PubMedGoogle Scholar
• Van Veen W , MarqollesA, MullerM, HigginsF, KoningsN. The homodimeric ATP-binding cassette transporter LmrA mediates multidrug transport by an alternating two-site (two-cylinder engine) mechanism, EMBO J.19 (11), 2503–2514 (2000).
   PubMed Web of Science ®Google Scholar
• Martin C , BerridgeG, HigginsF, MistryP, CharltonP, CallaghanR. Communication between multiple drug binding sites on P-glycoprotein. Mol. Pharmacol.58 (3), 624–632 (2000).
   PubMed Web of Science ®Google Scholar
• Leung CS , LeungSS, Tirado-RivesJ, JorgensenWL. Methyl effects on protein-ligand binding. J. Med. Chem.55 (9), 4489–4500 (2012).
   PubMed Web of Science ®Google Scholar
• Barreiro EJ , KummerleAE, Fraga, CAM. The methylation effect in medicinal chemistry. Chem. Rev.111 (9), 5215–5246 (2011).
   PubMed Web of Science ®Google Scholar
• Lemke TL , WilliamsDA, RocheVF, ZitoSW. Foye's Principles of Medicinal Chemistry (Seventh Edition).Lippincott Wiliiams and Wilkins, NY, USA (2013).
   Google Scholar
• Tsukamoto T . Tough times for medicinal chemists: are we to blame?ACS Med. Chem. Lett.4 (4), 369–370 (2013).
   PubMed Web of Science ®Google Scholar
• Joslyn AF , LuchkowskiE, TriggleDJ. Dimeric 1,4-dihydropyridines as calcium channel antagonists. J. Med. Chem.31 (8), 1489–1492 (1988).
   PubMed Web of Science ®Google Scholar
• Sauna ZE , AndrusMB, TurnerTM, AmbudkarSV. Biochemical basis of polyvalency as a strategy for enhancing the efficacy of P-glycoprotein (ABCB1) modulators: stipiamide homodimers separated with defined-length spacers reverse drug efflux with greater efficacy. Biochemistry43 (8), 2262–2271 (2004).
   PubMed Web of Science ®Google Scholar
• Namanja HA , HrycynaCA, ChmielewskiJet al. Toward eradicating HIV reservoirs in the brain: inhibiting P-glycoprotein at the blood-brain barrier with prodrug abacavir dimers. J. Am. Chem. Soc.134 (6), 2976–2980 (2011).
   PubMed Web of Science ®Google Scholar
• Pires MM , EmmertD, Hrycyna, CA, ChmielewskiJ. Inhibition of P-glycoprotein-mediated paclitaxel resistance by reversibly linked quinine homodimers. Mol. Pharmacol.75 (1), 92–100 (2009).
   PubMed Web of Science ®Google Scholar
• Pires MM , HrycynaCA, ChmielewskiJ. Bivalent probes of the human multidrug transporter P-glycoprotein. Biochemistry45 (38), 11695–11702 (2006).
   PubMed Web of Science ®Google Scholar